FiercePharma1h
JPM25, Day 1: J&J strikes $14.6B deal for Intra-Cellular Therapies
Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...
FiercePharma1h
After a 'reset' year for M&A, expect bigger deals in 2025: reports
The biopharma industry’s deal-a-palooza, better known as the J.P. Morgan Healthcare Conference, has kicked off in San ...
FiercePharma2h
Y-mAbs splits from commercial chief, tasks new hire with growing cancer drug sales
Y-mAbs Therapeutics is parting ways with its chief commercial officer and putting a new hire in charge of the cancer drug ...
FiercePharma3h
After Alkermes' makeover, CEO Richard Pops touts its pipeline program and rare biotech model
At the start of each of the last five years, the share price of Alkermes has increased. It’s the kind of steady trajectory ...
FiercePharma13h
Biogen, already a Sage partner and equity owner, offers to buy the rest of the neuro biotech
A yearslong partner of neuroscience player Sage, Biogen already owns 10.2% of the Cambridge, Massachusetts-based biotech, ...